BGC > Produktsuche > Rebastinib

Description:
Rebastinib is an orally bioactive inhibitor of Bcr-Abl that binds to and inhibits Bcr-Abl fusion oncoprotein. Rebastinib changes the conformation of the folded protein to disallow ligand-dependent and ligand-independent activation. It also exhibits inhibitory activity at SRC, LYN, FGR, HCK, KDR, FLT3, and Tie-2.

• Molecular Weight:553.598
• Melting Point:>181°C (dec.)
• Purity:≥98%

Molecular Formula:
C30H28FN7O3
Canonical SMILES:
CC(C)(C)C1=NN(C(=C1)NC(=O)NC2=C(C=C(C=C2)OC3=CC(=NC=C3)C(=O)NC)F)C4=CC5=C(C=C4)N=CC=C5
InChI:
InChI=1S/C30H28FN7O3/c1-30(2,3)26-17-27(38(37-26)19-7-9-23-18(14-19)6-5-12-33-23)36-29(40)35-24-10-8-20(15-22(24)31)41-21-11-13-34-25(16-21)28(39)32-4/h5-17H,1-4H3,(H,32,39)(H2,35,36,40)
InChIKey:
WVXNSAVVKYZVOE-UHFFFAOYSA-N
Appearance:
Off-White Solid
Application:
Antineoplastic Agents
Synonyms:
DCC2036; DCC-2036; DCC 2036; Rebastinib. 4-[4-[(5-tert-butyl-2-quinolin-6-ylpyrazol-3-yl)carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide